Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16356282 | 0.79 | PTGS1 (0.42) | POLBALDH1A1LMNAMAPTNPSR1 | |
| SCHEMBL8282201 | 0.76 | MPO (0.39) | ALDH1A1LMNAMAPTMEN1KMT2A | |
| SCHEMBL14881169 | 0.76 | PTGS1 (0.53) | ALDH1A1MGLLHPGDTSHRHSD17B10 | |
| SCHEMBL14881088 | 0.76 | PTGS1 (0.53) | ALDH1A1MGLLHPGDTSHRHSD17B10 | |
| SCHEMBL92102 | 0.73 | CYP1B1 (0.67) | CYP1B1POLBALDH1A1LMNAMEN1 | |
| SCHEMBL29969387 | 0.73 | CYP1B1 (0.67) | CYP1B1POLBALDH1A1LMNAMEN1 | |
| SCHEMBL10062480 | 0.73 | CYP1B1 (0.67) | CYP1B1POLBALDH1A1LMNAMAPT | |
| SCHEMBL6857906 | 0.73 | F2 (0.62) | CYP1B1POLBALDH1A1LMNAMAPT | |
| SCHEMBL13409576 | 0.72 | CASP3 (0.44) | POLBALDH1A1MAPTMGLLMEN1 | |
| Bromide SCHEMBL17510003 | 0.71 | CYP1B1 (0.64) | CYP1B1POLBALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013056355-A1 | PREPARATION OF HIGH MOLECULAR WEIGHT POLYMERS 8Y DIRECT ARYLATION AND HETEROARYLATION | UNIVERSITé LAVAL (CA) | 2013-04-25 | — | — | WO | disclosed |
| EP-1730142-B1 | NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2011-06-29 | — | — | EP | disclosed |
| US-7619094-B2 | Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | SCHERING CORPORATION (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-7173057-B2 | Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus | SCHERING CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093430-A1 | Novel ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus | PREP, PRSS1, P4HB | CYP1B1 1542/4885POLB 4046/4885ALDH1A1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.